Program Committee

The Program Committee is a group of talented and passionate members dedicated to building an impactful program. The committee's collaboration allows ISPOR to deliver a meaningful experience to attendees interested in advancing the use of real world evidence across regulatory-HTA-payer decision-making continuum.


Massoud Toussi, MBA, MSc, PhD, MD
Vice President, Global Head of RWE, Cytel, Paris, France
Shirley Wang, PhD
Associate Professor, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA


Francis Arickx
Head of the Directorate Pharmaceutical Policy, National Institute for Health and Disability Insurance (RIZIV INAMI), Brussels, Belgium

Dorthe Bartels, MSc, MBA
Senior Strategic Advisor - New Medicines, Amgros, Copenhagen, Denmark

Máirín Ryan, PhD
Deputy Chief Executive and Director of Health Technology Assessment, Health Information and Quality Authority (HIQA), Dublin, Ireland
Uwe Siebert, MD, MPH, MSc, ScD
UMIT TIROL - University for Health Sciences and Technology Hall in Tirol, Tyrol, Austria, Harvard Chan School of Public Health Harvard University, Boston, MA, USA

Kärt Veliste, MSc             
Service Manager, Department of Medicines and Medical Devices, Tervisekassa (Estonian Health Insurance Fund), Tallinn, Estonia

Patrice Verpillat, MD, MPH, PhD
Head of Real-World Evidence, European Medicines Agency (EMA), Amsterdam, Netherlands